Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that we have downed yet another cup of stimulation. For those who care, our flavor today has traces of Tennessee whiskey, and it already comes this way, believe it or not. In any event, feel free to join us or grab a bottle of whiskey-free water, if you prefer. Meanwhile, here are some items of interest. Have a lovely day and do keep in touch …
India’s health ministry recommended waiving clinical trials for critical drugs to treat such diseases as HIV, hepatitis, and tuberculosis if the medicines have already been approved in markets such as the U.S., Japan, the European Union, Canada, and Australia at least two years ago, the Economic Times informs us. However, some doctors tell PharmaBiz they have concerns about this policy.
Seven months after a generic EpiPen arrived, the more expensive brand-name device still accounts for more than one-quarter of the market, the Wall Street Journal notes. One reason is that middlemen take a cut, such as rebates, allowing them to profit from the sale of pricier medicines. For a typical brand-name drug listing for $300, a pharmacy benefit manager receives more than $37 in gross profit and a PBM gets $18, according to Pembroke Consulting.
About the Author Reprints
